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HIGHLIGHTS 
 Elderly patients with venous thromboembolism have a 3-year recurrence 
incidence of 15% 
 Unprovoked venous thromboembolism and proximal deep venous thrombosis 
are associated with recurrence 
 Many traditional risk factors for recurrence (e.g., male sex) fail to predict 
recurrence in the elderly 
 Recurrence carries a substantial case-fatality rate of over 20% in the elderly 
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ABSTRACT 
Background: Little is known about predictors and outcomes of recurrent venous 
thromboembolism in elderly patients. 
Methods: We prospectively followed up 991 patients aged ≥65 years with acute 
venous thromboembolism in a multicenter Swiss cohort study. The primary outcome 
was symptomatic recurrent venous thromboembolism. We explored the association 
between baseline characteristics and treatments and recurrent venous 
thromboembolism using competing risk regression, adjusting for periods of 
anticoagulation as a time-varying co-variate. We also assessed the clinical 
consequences (case-fatality, localization) of recurrent venous thromboembolism. 
Results: During a median follow-up period of 30 months, 122 patients developed 
recurrent venous thromboembolism, corresponding to a 3-year cumulative incidence 
of 14.8%. The case-fatality of recurrence was high (20.5%), particularly in patients 
with unprovoked (23%) and cancer-related venous thromboembolism (29%). After 
adjustment, only unprovoked venous thromboembolism (sub-hazard ratio [SHR] 1.67 
compared to provoked venous thromboembolism; 95% confidence interval [CI] 1.00-
2.77) and proximal deep vein thrombosis (SHR 2.41 compared to isolated distal deep 
vein thrombosis; 95% CI 1.07-5.38) were significantly associated with recurrence. 
Patients with initial pulmonary embolism were more likely to have another pulmonary 
embolism as a recurrent event than patients with deep vein thrombosis. 
Conclusions: Elderly patients with acute venous thromboembolism have a 
substantial long-term risk of recurrent venous thromboembolism and recurrence 
carries a high case-fatality rate. Only two factors, unprovoked venous 
thromboembolism and proximal deep vein thrombosis, were independently 
associated with recurrent venous thromboembolism, indicating that traditional risk 
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factors for venous thromboembolism recurrence (e.g., cancer) may be less relevant 
in the elderly. 
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INTRODUCTION 
Venous thromboembolism, pulmonary embolism and/or deep venous 
thrombosis, is common and has a high impact on morbidity and mortality.1 As venous 
thromboembolism tends to recur,2,3 the risk of recurrence is an important determinant 
of the duration of anticoagulant therapy. Several patient characteristics are 
associated with recurrent venous thromboembolism, including age,3,4 male sex,3,5 
obesity,4 localization of venous thromboembolism,6,7 unprovoked venous 
thromboembolism,3,8 cancer-related venous thromboembolism,2,3 prior venous 
thromboembolism,9 family history of venous thromboembolism,10 inflammatory bowel 
disease,11 chronic heart failure,12 leg paresis,13 varicose veins,4 elevated D-dimer at 
baseline,14 or thrombophilia.10,15 Treatment-related factors associated with venous 
thromboembolism recurrence include a suboptimal anticoagulation quality and the 
insertion of a vena cava filter,2,16 whereas thrombolysis,17 initial therapy with low-
molecular-weight heparin (LMWH),18 and concomitant use of statins or antiplatelet 
therapy may have a protective effect.3,19 Bleeding episodes may also be followed by 
a higher risk of recurrent venous thromboembolism, possibly owing to the interruption 
of anticoagulation.20 Elevated D-dimer after stopping anticoagulation and residual 
vein obstruction are also associated with recurrent venous thromboembolism.21,22 
Although elderly patients have a higher risk of venous thromboembolism due 
to multimorbidity and an prothrombotic hemostasis23,24 and persons aged ≥65 years 
comprise 55% of patients with acute venous thromboembolism,20 little is known about 
predictors and outcomes of recurrent venous thromboembolism in older patients. 
Prior studies reporting predictors of recurrent venous thromboembolism in the elderly 
were limited by a retrospective study design,20 use of administrative rather than 
clinical data,20 lack of information on anticoagulation duration or quality,12,20 or a 
follow-up of up to three months only.12 To fill this gap of knowledge, we explored the 
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association between patient characteristics, treatments, and the long-term risk of 
recurrent venous thromboembolism in a prospective cohort of elderly patients with 
acute venous thromboembolism. We also assessed the localization and the clinical 
consequences of recurrent venous thromboembolism. 
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METHODS 
Cohort sample 
The study was conducted between September 2009 and December 2013 as 
part of a prospective multicenter cohort study that assessed long-term medical 
outcomes and quality of life in elderly patients with symptomatic venous 
thromboembolism from all five university and four high-volume non-university 
hospitals in Switzerland. Consecutive patients aged ≥65 years with objectively 
confirmed symptomatic pulmonary embolism and/or deep vein thrombosis were 
identified in the inpatient and outpatient services of all participating study sites. 
Exclusion criteria were inability to provide informed consent (i.e., severe dementia), 
conditions incompatible with follow-up (i.e., terminal illness or place of living too far 
away from the study center), insufficient German or French-speaking ability, 
thrombosis at a different site than lower limb, catheter-related thrombosis or previous 
enrollment in the cohort. The study was approved by the institutional review board at 
each participating site. A detailed description of the study methods was published 
elsewhere.25 
 
Data collection 
Trained study nurses recorded baseline demographics (age, sex, body mass 
index), localization of index venous thromboembolism (pulmonary embolism, 
proximal deep vein thrombosis, distal deep vein thrombosis), type of index venous 
thromboembolism (provoked, unprovoked, cancer-related venous thromboembolism), 
medical history (current hospitalization, prior venous thromboembolism, family history 
of venous thromboembolism, inflammatory bowel disease, chronic heart failure, 
hemiparesis, hemiplegia or paraplegia, prior varicose vein surgery), laboratory 
findings (D-dimer values, Factor V Leiden mutation, prothrombin G20210A mutation), 
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medications at baseline (statins, antiplatelet therapy), and venous thromboembolism-
related treatments, including type of initial parenteral anticoagulation (LMWH, 
unfractionated heparin, fondaparinux, and danaparoid), thrombolysis, the insertion of 
a vena cava filter, and use of vitamin K antagonists, from all enrolled patients using 
standardized data collection forms. 
 
Predictors of recurrent VTE 
We abstracted the following patient baseline variables that have previously 
been described as predictors of venous thromboembolism recurrence from our 
database: age,3,4 male sex,3,5 obesity (defined as BMI ≥30kg/m2),4 localization of 
index venous thromboembolism (pulmonary embolism, proximal deep vein 
thrombosis, distal deep vein thrombosis),6,7 type of index venous thromboembolism 
(provoked, unprovoked, cancer-related),3,8 prior venous thromboembolism,9 family 
history of venous thromboembolism,10 inflammatory bowel disease,11 chronic heart 
failure,12 leg paresis (hemiparesis, hemiplegia, paraplegia),13 varicose vein surgery (a 
proxy for varicose veins),4 D-dimer levels at baseline,14 and thrombophilia (factor V 
Leiden or prothrombin G20210A mutation).10,15 Provoked venous thromboembolism 
was defined as venous thromboembolism following major surgery, estrogen therapy 
or immobilization (bed rest for more than 72 hours, travel in a sitting position for more 
than six hours, fracture or a cast of the lower extremity) during the last three months. 
We also abstracted the following treatment-related variables: use of statins and 
antiplatelet drugs at baseline,19,3 type of initial anticoagulation,18 systemic and 
catheter-related thrombolysis,17 the insertion of a vena cava filter,2 and all INR values 
measured during follow-up.16 
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Study outcomes 
The study outcome was the time to a recurrent venous thromboembolism 
following the index event, defined as new or recurrent pulmonary embolism or deep 
vein thrombosis (proximal and/or distal) based on previously published criteria.26,27 
We also assessed the occurrence of major bleeding, defined as fatal bleeding, a 
symptomatic bleeding in a critical site or organ (intracranial, intraspinal, intraocular, 
retroperitoneal, intraarticular, pericardial or intramuscular with compartment 
syndrome), a bleeding with a reduction in hemoglobin concentration of ≥ 20g/l or a 
bleeding leading to a transfusion of ≥2 units of packed red blood cells.28 
Follow-up included one telephone interview and two surveillance face-to-face 
evaluations during the first year of study participation and then semiannual contacts, 
alternating between telephone calls and face-to-face evaluations (clinic visits or home 
visits in house-bound patients), as well as periodic reviews of patient’s hospital chart 
in order to obtain information about the data and type of clinical events. If a clinical 
event had occurred, this information was complemented by reviewing medical charts 
and interviewing patient’s primary care physicians and family members. Moreover, 
nurses obtained information about the cause of death from hospital discharge letters 
and autopsy reports if available. A committee of three independent blinded clinical 
experts adjudicated all outcomes and classified the cause of death as definitely due 
to pulmonary embolism, possibly due to pulmonary embolism, or due to another 
cause. Death was judged to be a definite fatal pulmonary embolism if it was 
confirmed by autopsy or if it followed a clinically severe pulmonary embolism. Death 
in a patient who died suddenly without obvious cause was classified as possible fatal 
pulmonary embolism. Final classification was made on the basis of the full consensus 
of this committee. We also determined the localization of recurrent venous 
thromboembolism. 
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Statistical analyses 
We compared baseline characteristics among patients with and without 
recurrence of venous thromboembolism using the chi-squared test and the non-
parametric Wilcoxon rank-sum test as appropriate. We estimated the cumulative 
incidence of recurrent venous thromboembolism by localization (pulmonary 
embolism, proximal deep vein thrombosis, distal deep vein thrombosis) and type 
(provoked, unprovoked, and cancer-related) of the index venous thromboembolism 
event using Kaplan-Meier curves and compared groups using the log-rank test. In 
patients taking vitamin K antagonists, we compared the quality of anticoagulation, 
expressed by the time within the therapeutic INR range, in patients with and without 
recurrent venous thromboembolism. We calculated the mean percentage of time 
spent within (2.0-3.0), above (>3.0), and below (<2.0) the therapeutic INR range 
according to Rosendaal’s method.29 We also assessed the number of patients with a 
subtherapeutic anticoagulation (INR<2.0) at the time of recurrence and the number of 
patients with a major bleeding within three months prior to the venous 
thromboembolism recurrence. 
We explored the association between predictors and the time to a first venous 
thromboembolism recurrence using competing risk regression,30 accounting for non- 
venous thromboembolism-related death as a competing event. The method yields 
sub-hazard ratios (SHR) with corresponding 95% confidence intervals (CIs). We 
included all baseline characteristics and treatments into the models, except the 
insertion of a vena cava filter, because the number of patients with recurrent venous 
thromboembolism who received a filter was too small (n=2). To avoid model 
overfitting and instability, the models generally included a minimum of five events per 
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predictor variable.31 In addition, we included only patient baseline characteristics into 
the model in a sensitivity analysis, omitting all treatment variables. 
In the principal model, missing values were imputed using chained equations. 
Imputation models were based on all other variables as well as indicator variables for 
venous thromboembolism recurrence and death, and the duration of follow-up. In 
total, 20 imputed data sets were generated, which were analyzed as described above 
using Rubin’s rules to combine results across data sets.32 In a secondary model, 
patients with missing values were excluded (complete case analysis). Both analyses 
were repeated for the time after stopping anticoagulant therapy. All analyses were 
done using Stata 14 (Stata Corporation, College Station, Texas). 
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RESULTS 
Study sample 
Of 1863 screened patients with venous thromboembolism, we excluded 462 
who had ≥1 exclusion criterion and 398 who did not consent to participate (Figure 1). 
After the exclusion of another 12 patients who refused the use of their data or 
withdrew from the study within one day of enrollment, our final sample comprised 991 
patients. The median age was 75 years and 53% were men. Overall, 687 patients 
(69%) had pulmonary embolism ± deep vein thrombosis, 224 patients (23%) proximal 
deep vein thrombosis ±distal deep vein thrombosis, and 80 (8%) an isolated distal 
deep vein thrombosis. Except the somewhat higher proportion of proximal deep vein 
thrombosis as the initial event among patients with recurrent venous 
thromboembolism (34% vs. 21%), baseline characteristics and treatments did not 
differ between patients with and without recurrent venous thromboembolism (Table 
1). Overall, 11 patients (1.1%) died from the initial venous thromboembolism event. 
 
Recurrent venous thromboembolism 
The median follow-up was 30 months (interquartile range [IQR] 19-36). The 
overall cumulative incidence of recurrent venous thromboembolism was 14.8% at 3 
years. The cumulative incidence of venous thromboembolism recurrence was 13.1% 
for patients with pulmonary embolism ± deep vein thrombosis, 20.9% for patients with 
proximal deep vein thrombosis ±distal deep vein thrombosis, and 12.1% for patients 
with isolated distal deep vein thrombosis (P=0.047 by the logrank test) (Figure 2, 
Panel A). The cumulative incidence of recurrent venous thromboembolism did not 
differ by type of venous thromboembolism and was 12.6% for patients with provoked 
venous thromboembolism, 15.3% for patients with unprovoked venous 
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thromboembolism, and 16.2% for patients with cancer-related venous 
thromboembolism (P=0.579 by the log-rank test) (Figure 2, Panel B). 
The median duration of initial anticoagulation was 7 months (IQR 4-24) and 
differed by localization and type of venous thromboembolism. The median duration of 
initial anticoagulation was 11 months (IQR 6-24) for patients with pulmonary 
embolism ± deep vein thrombosis, 6 months (IQR 3–20) for patients with proximal 
deep vein thrombosis ±distal deep vein thrombosis, and 3 months (IQR 2–6) for 
patients with isolated distal deep vein thrombosis. The median duration of initial 
anticoagulation was 6 months (IQR 3-18) for patients with provoked venous 
thromboembolism, 12 months (IQR 6-30) for patients with unprovoked venous 
thromboembolism, and 5 months (IQR 2-10) for patients with cancer-related venous 
thromboembolism, the latter being determined by the limited survival time. 
We could assess the quality of oral anticoagulation in 821 out of 991 (83%) 
patients who received vitamin K antagonists and for whom INR values were 
available. The mean time spent in the therapeutic (2.0-3.0), supratherapeutic (>3.0) 
and subtherapeutic (<2.0) INR range did not differ in patients with and without 
venous thromboembolism recurrence (Table 2). In 31 of 122 patients (25%), the 
recurrent event occurred under anticoagulant therapy. At the time of recurrence, 10 
of 27 (37%) patients receiving vitamin K antagonists had a subtherapeutic INR 
(<2.0). Of the 122 patients with recurrent venous thromboembolism, 9 (7.4%) had a 
major bleed within three months prior to recurrence. 
 
Predictors of recurrent venous thromboembolism 
Considering the entire follow-up period, proximal deep vein thrombosis (adjusted SHR 
2.41 compared to isolated distal deep vein thrombosis; 95% CI 1.07-5.38) and unprovoked 
venous thromboembolism (adjusted SHR 1.67 compared to provoked venous 
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thromboembolism; 95% CI 1.00-2.77) as the initial event were associated with recurrent 
venous thromboembolism (Table 3). While proximal deep vein thrombosis as the initial event 
was no longer statistically significantly associated with recurrence after the initial period of 
anticoagulation, unprovoked venous thromboembolism remained associated with recurrence 
after stopping initial anticoagulation. Although patients taking statins were somewhat less 
likely to develop recurrent venous thromboembolism, the association between statin use and 
recurrent venous thromboembolism generally failed to achieve statistical significance, except 
for the period after stopping initial anticoagulation in the complete case analysis (adjusted 
SHR 0.46;  
95% CI 0.23-0.93). When we included only patient baseline characteristics (without 
treatments) into the model, the results did not change markedly (results not shown). 
Clinical characteristics and outcomes of recurrent venous thromboembolism 
Of the 122 venous thromboembolism recurrences, 82 (67.2%) were pulmonary 
embolism ± deep vein thrombosis, 31 (25.4%) proximal deep vein thrombosis ±distal 
deep vein thrombosis, and 9 (7.4%) isolated distal deep vein thrombosis. Patients 
with initial pulmonary embolism were more likely to have recurrent pulmonary 
embolism than patients with initial deep vein thrombosis (74% vs. 57%) (Table 4). 
Patients with initial provoked venous thromboembolism were less likely to have 
recurrent pulmonary embolism than patients with initial unprovoked or cancer-related 
venous thromboembolism (50% vs.71% for each comparison). Overall, 25 of 122 
(20.5%) recurrent events were fatal. The case-fatality rate was highest in patients 
with initial pulmonary embolism ± deep vein thrombosis (23%) and those with cancer-
related venous thromboembolism (29%) (Table 4). 
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DISCUSSION 
Our results show that elderly patients with acute venous thromboembolism 
have a cumulative recurrence risk of 15% within three years, with a substantial case-
fatality rate of over 20% following recurrence. Among the multiple predictors explored 
in various analyses, only unprovoked venous thromboembolism and proximal deep 
vein thrombosis as the initial event were independently associated with recurrent 
venous thromboembolism over the entire follow-up. After stopping initial 
anticoagulation, only unprovoked venous thromboembolism remained associated 
with recurrence. Commonly cited risk factors for venous thromboembolism 
recurrence, such as cancer, and treatments were not consistently associated with 
recurrence in our sample of elderly patients. Patients with initial pulmonary embolism 
were more likely to have another pulmonary embolism as a recurrent event. 
The 3-year cumulative incidence of recurrent venous thromboembolism in our 
prospective study (15%) was similar as in a retrospective study of 1048 elderly 
subjects (17%),20 but slightly higher than in prior mixed retrospective/prospective 
cohort of 1223 elderly patients (10%).33 While these studies did not report the case-
fatality following recurrent venous thromboembolism, the case-fatality rate of 20% 
observed in our study of elderly subjects is substantially higher than in younger 
patients, with a case-fatality of 11% during the first three months of anticoagulation 
and case-fatality of 4% after stopping anticoagulation.34 The case-fatality of recurrent 
venous thromboembolism was highest in patients initially presenting with pulmonary 
embolism (23%) and those with cancer-related venous thromboembolism (29%). The 
slightly higher cumulative incidence of venous thromboembolism recurrence in 
patients with proximal deep vein thrombosis as compared to patients with pulmonary 
embolism is most likely due to the shorter anticoagulation duration in patients with 
proximal deep vein thrombosis without pulmonary embolism (6 vs. 11 months). 
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Although we examined multiple potential predictors of venous 
thromboembolism recurrence, we found only two variables, unprovoked venous 
thromboembolism and proximal deep vein thrombosis, to be associated with 
recurrent venous thromboembolism. As shown in a prior study of younger patients,35 
unprovoked venous thromboembolism carries a substantial recurrence risk of up to 
27% per year and long-term anticoagulant therapy is recommended in patients with 
unprovoked venous thromboembolism who are at low or moderate risk of bleeding.36 
Consistent with the findings from our study, an analysis of individual participants’ data 
from seven trials showed a lower risk of recurrent venous thromboembolism after an 
isolated distal deep vein thrombosis compared to proximal deep vein thrombosis.8 
Evidence from a randomized trial suggests that anticoagulation may not be superior 
to symptomatic treatment in patients with isolated distal deep vein thrombosis and 
current guidelines acknowledge that symptomatic treatment and observation rather 
than anticoagulant treatment is possible in selected patients with isolated distal deep 
vein thrombosis.36,37 Although active cancer is a well-established risk factor for 
venous thromboembolism recurrence,2,3 our study and two previous studies found no 
association between cancer-related venous thromboembolism and recurrence in the 
elderly.12,20 While we cannot exclude the possibility that cancer may be a weaker risk 
factor for venous thromboembolism recurrence in the elderly than in younger 
patients, another potential explanation for this finding is survival bias. Patients with 
cancer who have a very limited survival time may die from cancer before developing 
recurrent venous thromboembolism, mitigating the relationship between cancer and 
recurrence. Consistent with the results from two prior studies of older patients,20,33 we 
did not find an association between advancing age and increased recurrent venous 
thromboembolism in elderly patients. 
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The localization of recurrent venous thromboembolism appears to reflect the 
site of the initial event in elderly patients: those with an initial pulmonary embolism 
more often present with recurrent pulmonary embolism again, whereas those with 
initial deep vein thrombosis more often have recurrent deep vein thrombosis without 
pulmonary embolism, a phenomenon well known in younger patients.7 However, 
there is currently no evidence that the extension of anticoagulation duration in 
patients with pulmonary embolism is prognostically favorable. 
Overall, our findings suggest that except for the type and localization of 
venous thromboembolism (i.e., unprovoked venous thromboembolism and proximal 
deep vein thrombosis), previously described clinical predictors of recurrent venous 
thromboembolism may not apply to the elderly and may not be particularly useful in 
risk-stratifying older persons with acute venous thromboembolism. As older patients 
with venous thromboembolism have a 2-fold risk of anticoagulation-related major 
bleeding, 20 it is challenging to select elderly patients with venous thromboembolism 
who could benefit from longer anticoagulation durations. 
Our study has several potential limitations. First, our cohort included patients 
≥65 years only, precluding a direct comparison of recurrence predictors and 
outcomes in older vs. younger patients. Second, because of the observational study 
design, the durations of anticoagulation differed by localization and type of venous 
thromboembolism, which may cause spurious associations (confounding by 
treatment). We attempted to minimize the risk of confounding by treatment by 
adjusting periods of anticoagulation as a time-varying co-variate and excluded the 
period of initial anticoagulation in a sensitivity analysis. Third, although the number 
and severity of risk factors can change over time and influence the rate of recurrent 
venous thromboembolism,3 we could not assess the effect of such changes on the 
risk of venous thromboembolism in our cohort. Fourth, as almost no direct oral 
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anticoagulants were used in Switzerland during the study period, our results may not 
be extrapolable to patients treated with such anticoagulants. Finally, we explored a 
large number of potential baseline predictors and treatments but could not reliably 
examine the association between follow-up predictors and recurrent venous 
thromboembolism, such as the post-anticoagulation D-dimer level or residual vein 
thrombosis. 
In conclusion, elderly patients with acute venous thromboembolism have a 
substantial long-term risk of recurrent venous thromboembolism, and recurrence has 
a high case-fatality rate of over 20%. Patients with initial pulmonary embolism were 
more likely to have another pulmonary embolism as a recurrent event. Only two 
factors, unprovoked venous thromboembolism and proximal deep vein thrombosis, 
were independently associated with recurrent venous thromboembolism, indicating 
that traditional risk factors for recurrent venous thromboembolism (e.g., male sex, 
cancer) may be less relevant in the elderly. 
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FIGURE LEGENDS 
Figure 1. 
Patient flow chart. 
 
Figure 2. 
Panel A. Kaplan-Meier estimates of recurrent VTE by localization of the index 
event 
The 3-year cumulative incidence for recurrent VTE was 13.1% in patients with 
PE±DVT, 20.9% in patients with proximal DVT±distal DVT, and 12.1% in patients 
with isolated distal DVT (P=0.047 by the log-rank test). 
 
Panel B. Kaplan-Meier estimates of recurrent VTE by type of the index event 
The 3-year cumulative incidence for recurrent VTE was 12.6% for provoked, 15.3% 
for unprovoked, and 16.2% for cancer-related VTE (P=0.579 by the log-rank test). 
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Figure 1 
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Table 1.  Patient baseline characteristics and treatments by VTE recurrence 
  All Recurrence No recurrence  
 (n=991) (n=122) (n=869)  
Characteristic* n (%) or median (interquartile range) P-value 
Baseline characteristics     
Patient age, years 75 (69-81) 75 (69-80) 75 (69-81) 0.838 
Male sex 528 (53) 65 (53) 463 (53) 1.000 
Body mass index ≥30kg/m2 242 (24) 35 (29) 207 (24) 0.262 
Localization of index VTE    0.008 
  PE ±DVT 687 (69) 73 (60) 614 (71)  
  Proximal DVT ±distal DVT 224 (23) 41 (34) 183 (21)  
  Isolated distal DVT 80 (8) 8 (7) 72 (8)  
Type of index VTE    0.176 
  Provoked VTE† 215 (22) 22 (18) 193 (22)  
  Unprovoked VTE 598 (60) 83 (68) 515 (59)  
  Cancer-related VTE‡ 178 (18) 17 (14) 161 (19)  
Hospital-acquired VTE 184 (19) 16 (13) 168 (19) 0.107 
Prior VTE 283 (29) 33 (27) 250 (29) 0.749 
Family history of VTE 165 (17) 19 (16) 146 (17) 0.796 
Inflammatory bowel disease§ 32 (3) 7 (6) 25 (3) 0.101 
Chronic heart failure** 76 (8) 5 (4) 71 (8) 0.145 
Leg paresis†† 29 (3) 4 (3) 25 (3) 0.773 
Prior varicose vein surgery‡‡ 136 (14) 16 (13) 120 (14) 1.000 
Factor V Leiden mutation 82 (8) 10 (8) 72 (8) 1.000 
Prothrombin G20210A mutation 49 (5) 5 (4) 44 (5) 0.824 
D-dimer at baseline, ng/mL 2506 
(1573-3817) 
2730 
(1744-4133) 
2471 
(1567-3766) 
0.179 
Treatments     
Statin therapy§§ 241 (24) 21 (17) 220 (25) 0.055 
Antiplatelet therapy*** 321 (32) 39 (32) 282 (32) 1.000 
Type of initial anticoagulation    0.997 
  Low-molecular-weight heparin 465 (47) 57 (47) 408 (47)  
  Unfractionated heparin 333 (34) 41 (34) 292 (34)  
  Fondaparinux 158 (16) 20 (16) 138 (16)  
  Danaparoid 1 (0) 0 (0) 1 (0)  
  No anticoagulation 34 (3) 4 (3) 30 (3)  
Thrombolysis††† 30 (3) 4 (3) 26 (3) 0.779 
Vena cava filter 11 (1) 2 (2) 9 (1) 0.635 
 
Abbreviations: VTE=venous thromboembolism; PE=pulmonary embolism; DVT=deep venous 
thrombosis. 
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*Data were missing for BMI (1%), family history of VTE (1%), Factor V Leiden mutation (10%), 
Prothrombin G20210A mutation (10%), and D-dimer at baseline (15%). 
†Major surgery, estrogen therapy or immobilization (bed rest for more than 72 hours, voyage in a sitting 
position for more than 6 hours, fracture or a cast of the lower extremity) during the last 3 months. 
‡Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, or palliative care during 
the last 3 months. 
§Crohn’s disease or ulcerative colitis. 
**Known history of systolic or diastolic heart failure, left or right heart failure, forward or backward heart 
failure, or a known left ventricular ejection fraction of <40%. 
††Hemiparesis, hemiplegia, paraplegia. 
‡‡Surgical varicose vein removal, does not include non-invasive procedures (sclerotherapy, laser 
radiofrequency). 
§§Treatment with a statin at initial admission. 
***Treatment with aspirin, clopidogrel, prasugrel, or aspirin/dipyridamole at initial admission. 
†††Systemic or catheter-directed thrombolysis. 
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Table 2.  Mean percentage of time in a given INR range 
INR range* All VTE recurrence No VTE recurrence  
 Mean % (SD) P-value 
2.0-3.0 62 ± 23 60 ± 26 63 ± 22 0.194 
>3.0 15 ± 17 15 ± 19 15 ± 17 0.810 
<2.0 23 ± 21 26 ± 24 22 ± 21 0.117 
 
Abbreviations: VTE=venous thromboembolism; SD=standard deviation; INR=international normalized 
ratio. 
*Data were missing for 40 of 861 (4.6%) taking vitamin K antagonists. 
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Table 3.  Predictors of recurrent VTE 
 Entire follow-up period After initial anticoagulation only 
 Multiple 
imputations 
Complete case 
analysis 
Multiple 
imputations 
Complete case 
analysis 
n events / N patients 122/991 101/822 93/559 77/473 
Predictors SHR (95% CI) SHR (95% CI) SHR (95% CI) SHR (95% CI) 
Baseline characteristics     
Patient age, years 1.00 (0.97-1.03) 1.00 (0.97-1.03) 1.00 (0.96-1.03) 1.00 (0.96-1.04) 
Male sex 0.96 (0.65-1.43) 0.97 (0.63-1.48) 0.79 (0.50-1.24) 0.82 (0.50-1.34) 
Body mass index ≥30kg/m2 1.26 (0.84-1.90) 1.40 (0.90-2.18) 1.31 (0.82-2.08) 1.48 (0.88-2.48) 
Localization of index VTE     
  Isolated distal DVT Reference Reference Reference Reference 
  PE±DVT 2.00 (0.91-4.38) 2.20 (0.91-5.32) 1.51 (0.68-3.32) 1.75 (0.72-4.26) 
  Proximal DVT±distal DVT 2.41 (1.07-5.38) 2.60 (1.04-6.47) 1.62 (0.70-3.76) 1.71 (0.66-4.44) 
Type of index VTE     
  Provoked VTE* Reference Reference Reference Reference 
  Unprovoked VTE 1.67 (1.00-2.77) 2.04 (1.14-3.66) 1.80 (1.02-3.16) 2.16 (1.15-4.06) 
  Cancer-related VTE† 1.08 (0.55-2.12) 1.29 (0.60-2.77) 1.26 (0.58-2.71) 1.55 (0.66-3.63) 
Prior VTE 1.55 (1.00-2.41) 1.50 (0.92-2.43) 1.42 (0.84-2.42) 1.35 (0.76-2.40) 
Family history of VTE 0.86 (0.52-1.43) 0.93 (0.54-1.59) 0.86 (0.48-1.52) 0.91 (0.49-1.68) 
Inflammatory bowel disease‡ 1.76 (0.80-3.88) 2.10 (0.98-4.52) 1.23 (0.43-3.52) 1.62 (0.60-4.35) 
Chronic heart failure§ 0.65 (0.25-1.70) 0.59 (0.21-1.67) 0.63 (0.18-2.21) 0.43 (0.10-1.89) 
Leg paresis** 1.57 (0.50-4.97) 0.82 (0.18-3.75) 1.98 (0.47-8.32) 0.60 (0.07-4.86) 
Prior varicose vein surgery†† 1.00 (0.57-1.76) 0.95 (0.49-1.81) 0.98 (0.52-1.85) 0.85 (0.40-1.82) 
Factor V Leiden mutation 0.86 (0.42-1.75) 0.77 (0.36-1.65) 0.51 (0.18-1.44) 0.43 (0.15-1.27) 
Prothrombin G20210A mutation 0.97 (0.37-2.52) 1.03 (0.39-2.70) 0.72 (0.18-2.96) 0.66 (0.16-2.62) 
D-dimer at baseline, ng/mL (log 
transformed) 
1.11 (0.79-1.54) 1.09 (0.78-1.52) 1.19 (0.79-1.78) 1.15 (0.76-1.74) 
Treatments     
Statin therapy‡‡ 0.60 (0.35-1.04) 0.62 (0.35-1.12) 0.53 (0.28-1.02) 0.46 (0.23-0.93) 
Antiplatelet therapy§§ 1.31 (0.84-2.05) 1.21 (0.76-1.92) 1.16 (0.68-1.96) 1.14 (0.66-1.95) 
Type of initial anticoagulation     
  No anticoagulation Reference Reference Reference Reference 
  LMWH 1.02 (0.33-3.15) 0.71 (0.23-2.21) 0.96 (0.27-3.39) 0.71 (0.20-2.58) 
  Others (UFH, Fondaparinux, 
   Danaparoid) 
1.09 (0.36-3.30) 0.85 (0.28-2.56) 1.02 (0.30-3.51) 0.83 (0.24-2.90) 
Thrombolysis*** 1.96 (0.68-5.64) 1.84 (0.57-5.87) 0.99 (0.17-5.61) 1.38 (0.27-7.19) 
 
Abbreviations: SHR=sub-hazard ratio; CI=confidence interval; VTE=venous thromboembolism; 
PE=pulmonary embolism; DVT=deep venous thrombosis; LMWH=low-molecular-weight heparin; 
UFH=unfractionated heparin. 
*Major surgery, estrogen therapy or immobilization (bed rest for more than 72 hours, travel in a sitting 
position for more than 6 hours, fracture or a cast of the lower extremity) during the last 3 months. 
†Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, or palliative care during 
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the last 3 months. 
‡Crohn’s disease or ulcerative colitis. 
§Known history of systolic or diastolic heart failure, left or right heart failure, forward or backward heart 
failure, or a known left ventricular ejection fraction of <40%. 
**Hemiparesis, hemiplegia, paraplegia. 
††Surgical varicose vein removal, does not include non-invasive procedures (sclerotherapy, laser 
radiofrequency). 
‡‡Treatment with a statin at initial admission. 
§§Treatment with aspirin, clopidogrel, prasugrel, or aspirin/dipyridamole at initial admission. 
***Systemic or catheter-directed thrombolysis. 
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Table 4.  Recurrence characteristics and outcomes 
 Type of recurrent VTE 
 
All Fatal PE±DVT 
Proximal DVT 
±distal DVT 
Isolated 
distal DVT 
Index VTE N n/N(%) n/N(%) n/N(%) n/N(%) 
All patients 122 25/122 (21) 82/122 (67) 31/122 (25) 9/122 (7) 
Localization of index VTE      
PE±DVT 73 17/73 (23) 54/73 (74) 13/73 (18) 6/73 (8) 
Proximal DVT±distal DVT 41 7/41 (17) 23/41 (56) 16/41 (39) 2/41 (5) 
Isolated distal DVT 8 1/8 (13) 5/8 (63) 2/8 (25) 1/8 (13) 
Type of index VTE      
Provoked VTE* 22 1/22 (5) 11/22 (50) 9/22 (41) 2/22 (9) 
Unprovoked VTE 83 19/83 (23) 59/83 (71) 18/83 (22) 6/83 (7) 
Cancer-related VTE† 17 5/17 (29) 12/17 (71) 4/17 (24) 1/17 (6) 
 
Abbreviations: VTE=venous thromboembolism; PE=pulmonary embolism; DVT=deep venous 
thrombosis. 
*Major surgery, estrogen therapy or immobilization (bed rest for more than 72 hours, travel in a sitting 
position for more than 6 hours, fracture or a cast of the lower extremity) during the last 3 months. 
†Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, or palliative care during 
the last 3 months. 
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